1. Home
  2. DRH vs AGIO Comparison

DRH vs AGIO Comparison

Compare DRH & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

N/A

Current Price

$9.83

Market Cap

1.9B

Sector

Real Estate

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$30.73

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DRH
AGIO
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DRH
AGIO
Price
$9.83
$30.73
Analyst Decision
Buy
Buy
Analyst Count
9
8
Target Price
$9.81
$36.63
AVG Volume (30 Days)
2.7M
805.6K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
3.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$103.08
Revenue Next Year
$2.30
$126.67
P/E Ratio
$38.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.19
$22.24
52 Week High
$10.24
$46.00

Technical Indicators

Market Signals
Indicator
DRH
AGIO
Relative Strength Index (RSI) 60.48 67.90
Support Level $8.99 $26.57
Resistance Level $10.24 $43.72
Average True Range (ATR) 0.29 1.08
MACD 0.01 0.37
Stochastic Oscillator 63.89 98.44

Price Performance

Historical Comparison
DRH
AGIO

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: